Literature DB >> 7949636

Effect of single and multiple administrations of cisapride on postprandial gallbladder emptying in healthy humans.

M Takaoka1, Y Kubota, K Fujimura, M Ogura, H Kin, S Yamamoto, K Inoue.   

Abstract

Effects of a clinical dose of the prokinetic drug, cisapride, on postprandial gallbladder emptying were evaluated in 8 healthy normal volunteers. Gallbladder and gastric emptying after a liquid test meal were simultaneously measured by ultrasonography. Compared with placebo, a single oral dose of cisapride (5 mg) accelerated gastric emptying, but not gallbladder contraction. Cisapride enhanced gallbladder refilling. The same individuals took oral cisapride (15 mg TID) for 14 days, and were reassessed on the following day after oral 5 mg of cisapride. Fasting gallbladder volume was significantly increased. Although gallbladder contractility was not affected, the residual volume was significantly large. Gastric emptying rate returned to the control value. Fasting and post-test meal plasma CCK levels were not significantly attenuated by either single or multiple administration of cisapride. These results suggest that a clinical dose of cisapride may attenuate gallbladder motor function via mechanisms other than direct neural stimulation of the gallbladder.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949636     DOI: 10.2169/internalmedicine.33.381

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Mechanisms of cisapride affecting gallbladder motility.

Authors:  R von Kiedrowski; S Huijghebaert; R Raedsch
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

2.  Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.

Authors:  M J Veysey; P Malcolm; A I Mallet; P J Jenkins; G M Besser; G M Murphy; R H Dowling
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 3.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.